KCM
MIST icon

Key Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

Key Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-212
Closed -$252 – 775
2026
Q1 		$252 Hold
212
– – ﹤0.01% 662
2025
Q4 		$428 Buy
+212
New +$457 ﹤0.01% 488

Other funds holding MIST

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
BRG
Bay Rivers Group Williamsburg, Virginia $293M AUM 48.17% 1-Year Est. Return
OE
October Effect Virginia Beach, Virginia $106M AUM 85.28% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
SC
Stephenson & Company San Clemente, California $213M AUM 15.03% 1-Year Est. Return
TFG
Taylor Financial Group Roanoke, Virginia $182M AUM 21.76% 1-Year Est. Return
AWM
AE Wealth Management Topeka, Kansas $21.5B AUM 26.98% 1-Year Est. Return
VR
Vision Retirement Ridgewood, New Jersey $414M AUM

Key Capital Management's MIST Position: Q2 2026 in Review

Key Capital Management sold out of Milestone Pharmaceuticals (MIST) in Q2 2026, closing a stake of 212 shares — an estimated $252 sold.

Key Capital Management first reported a position in MIST in Q4 2025 and held it in 2 quarters. The position peaked at $428 in Q4 2025. 18 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Key Capital Management reported no remaining Milestone Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Key Capital Management sold 212 Milestone Pharmaceuticals shares in Q2 2026, an estimated $252.
  • Key Capital Management first reported a position in Milestone Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Key Capital Management's Milestone Pharmaceuticals position peaked at $428 in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Key Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.